

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 21, 2021

EYENOVIA, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or other jurisdiction
of incorporation)

001-38365
(Commission
File Number)

47-1178401
(IRS Employer
Identification No.)

295 Madison Avenue, Suite 2400, New York, NY
(Address of Principal Executive Offices, and Zip Code)

(917) 289-1117
Registrant's Telephone Number, Including Area Code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

(Title of each class)	(Trading Symbol)	(Name of each exchange on which registered)
Common stock, \$0.0001 par value	EYEN	The Nasdaq Stock Market (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01. Other Events.

Attached hereto as Exhibit 99.1 and incorporated herein by reference is a corporate update presentation Eyenovia, Inc. intends to use with various investors and analysts.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1</u>	<u>Eyenovia, Inc. corporate update presentation dated June 2021</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EYENOVIA, INC.

Date: June 21, 2021

/s/ John Gandolfo
John Gandolfo
Chief Financial Officer



eyenovia

Making it Possible

June 2021

Forward-Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

In addition, such statements could be affected by risks and uncertainties related to, among other things: volatility and uncertainty in the global economy and financial markets in light of the COVID-19 pandemic; fluctuations in our financial results; the timing and our ability or the ability of our licensees to submit applications for, obtain and maintain regulatory approvals for our product candidates; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology and potential revenues from licensing transactions; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize certain of our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for certain of our product candidates; risks of our ongoing clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; our ability to raise additional money to fund our operations for at least the next twelve months as a going concern; intellectual property risks; and our competitive position.

Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Investment Highlights

Late-stage therapeutics pipeline

MicroStat (Mydcombi™) for mydriasis (pupil dilation):

NDA PDUFA date expected October 28, 2021

MicroPine for pediatric progressive myopia:

Phase 3 CHAPERONE study full enrollment expected 4Q 2021

MicroLine for presbyopia (improved near vision):

Phase 3 VISION-1 study successfully completed 2Q 2021

Development and commercialization partnerships

with leading global eyecare companies validate technology and provide significant non-dilutive capital.

Arctic Vision – Announced August 2020 with MicroPine and MicroLine for Greater China and South Korea

Bausch Health – Announced October 2020 for MicroPine in the US and Canada

Clinically validated
in multiple Phase 2 and
Phase 3 studies

Platform technology
allows for potential pipeline
expansion into further high-value
ophthalmic indications



A leading ophthalmic company
developing next-generation therapeutics
delivered using its proprietary Optejet®
microdose array print (MAP™) dispensing
technology

Leadership Team



Dr. Sean Ianchulev,
MD, MPH
CEO, CMO and Co-Founder

- Head of ophthalmology research and directed development and FDA approval of Lucentis, most successful ophthalmic drug for Genentech
- IanTech founder for cataract device approved by FDA in 2016 and inventor of Intra-operative Aberrometry at Wavetec-Alcon/Novartis
- CMO of Transcend Medical (acquired by Alcon/Novartis)



John Gandolfo
CFO



Michael Rowe
COO



Jennifer Clasby
VP Regulatory, Clinical and Quality



Luke Clauson
VP R&D, Manufacturing



Late-Stage Ophthalmic Pipeline for US Registration in Markets Valued Over \$12.7 Billion

Product Candidate	Therapeutic Area	Pre-Clinical/ Formulation	Phase 1	Phase 2	Phase 3	NDA
MydCombi™ (trop+phen)	Pharmacologic Mydriasis	\$250M+ US market opportunity*			MIST-1 MIST-2	
MicroLine ¹ (pilocarpine)	Improvement in near vision in patients with presbyopia	~\$7.7B US market opportunity ²			VISION-1	VISION
MicroPine ³ (atropine)	Reduction of pediatric myopia progression	\$5B+ US market opportunity*			CHAPERONE ⁴	

* Estimate only

¹ Out-licensed to Arctic Vision in Greater China and South Korea

² Estimate from DelveInsight Presbyopia report, December 2020


³ Out-licensed to Bausch Health in the US and Canada, and Arctic Vision in Greater China and South Korea

⁴ CHAPERONE oversight and costs assumed by Bausch Health

Potential pipeline expansion activities leveraging Optejet technology are ongoing

Potential Topical US Ophthalmic Market For Platform Technology*

Market Size Estimates for the United States
(in US\$ Billions)



Current Portfolio: ~\$12.9 Billion*

Existing Eyeovia portfolio in mydriasis, presbyopia, and myopia, with late-stage, first-in-class therapeutics.

Anti-Infectives: ~\$650 Million¹

Eliminate contamination from poor usage of eyedropper bottles.

Anti-Inflammatories: ~\$1.4 Billion¹

Reduce IOP spikes due to high doses of steroids.

Prescription Dry Eye: ~\$1.6 Billion²

Improve clinical probability of success. Enable patients, especially the elderly, to better instill medication for improved results. Multi-dose preservative free options.

Glaucoma: ~\$3 Billion³

Improve systemic safety profile and allow for development of PGA + BB fixed combinations. Improvement in topical (e.g., hyperemia) and systemic AE profile. Multi-dose preservative free options.

Standard Eyedroppers Have Limited Therapeutic Approaches

- Potential overexposure to drug and preservatives
 - Conventional droppers can overdose the eye by as much as 300%+¹
 - Known to cause ocular and systemic side effects¹



- Protruding tip may create cross-contamination risk
 - More than 50% of administrations touch ocular surface²
- More difficult to use with poor compliance
 - Requires head tilting and aiming which may be compromised in pediatric and elderly populations
 - No dosage reminders or tracking which may lead to missed doses

Optejet Microdose Array Print (MAP) Technology Designed for Optimal Drug Delivery

Precise, Physiological Dosing:

Directly coats the cornea with ~80% less exposure to drug and preservative toxicity (based on 8 μ L dose).¹
Designed to eliminate drug overflow for a more comfortable patient experience.

Efficacy:

Demonstrated statistical and clinically significant efficacy in both IOP reduction and pharmacological mydriasis.^{2,3}

Safety:

Low systemic drug absorption and good ocular tolerability.^{3,4}

Non-protruding nozzle for no-touch spray application, potentially minimizing risk of cross contamination seen with traditional eyedroppers.



Ease of Use:

Horizontal drug delivery means no need to tilt the head back.

Demonstrated first-time success with both medical professionals and patients.²

Compliance and Adherence:

Can be paired with smart devices to enable dosage reminders and tracking.




Optejet: Significant Clinical Experience and Validation



Five Phase 2 or Phase 3 clinical trials to date featured in dozens of publications and major meetings including ASCRS, AAO, AAOpt, OIS and EYEcelerator.

Reduced Systemic Levels





Drugs in traditional eyedroppers can **enter systemic blood circulation** and may cause **significant side effects**.¹

Microdose delivery of phenylephrine 10% (PE- μ D) **was associated with significantly less systemic exposure** than traditional eye drops (PE 10%).²

Optejet: Demonstrated Effectiveness in Multiple Phase 3 Studies

Microdosing a fixed combination of tropicamide-phenylephrine had a superior mydriatic effect compared to either component formulation¹


Microdose Efficacy



Real Improvement in Real World Use

In an ongoing late-stage trial, among the initial group of children using the Optejet once-daily, average compliance was nearly 90% during 6 consecutive months of Optejet use

This compares favorably to the approximately 50% compliance rate for pediatric medications as a whole, or the 59 – 69% range published for adult topical ophthalmic drug users



Estimated Gross Margins Based on \$100/Month Price¹

82% - 94%

Next-Generation Ophthalmic Therapeutics

- Eyenovia's microdose therapeutics follow the 505(b)(2) registration pathway and are not currently regulated as medical devices or drug-device combinations
- The FDA categorizes the Optejet as a container closure system

Eyenovia Products Aim to Provide Competitive Pharmaceutical Margins:

- All pipeline products are Eyenovia's own proprietary micro-formulations
- Eyenovia currently owns the pharma-economics of the entire prescription value chain
- MicroLine has strong potential as a cash-pay cosmeceutical




Etiology

- The progressive loss of ability to focus on nearby objects
- Non-preventable, age-related hardening of the lens



Symptoms

- Tendency to hold reading material farther away to make the letters clearer
- Blurred vision at normal reading distance
- Eye strain, headaches after reading or doing close-up work



Risk Factors

- Age
- Medical conditions and co-morbidities such as cardiovascular conditions, multiple sclerosis, and type 2 diabetes
- Drugs associated with premature symptoms include antidepressants, anti-histamines and diuretics



Diagnosis

- Basic eye exam, with refraction assessment



May 2021: Phase 3 VISION-1 trial achieves primary endpoint

- ➔ Statistically significant proportion of subjects in treatment arm achieved three-line or more improvement in distance corrected near visual acuity
- ➔ Well tolerated with only mild adverse events; less than 3% brow ache
- ➔ 71% of study participants reported strong interest in using MicroLine if approved





Registrational Phase 3 VISION-2 study planned for H2 2021

- ➔ Topline data anticipated in H1 2022

VISION-1 Study Design

- Double-masked, placebo-controlled, cross-over superiority trial
 - Phase 3 (microdosed pilocarpine 1%, 2% and placebo)
- Primary endpoint: binocular distance corrected near visual acuity
- First patient enrolled in VISION 1: December 2020





7 times more responders with Microline 2% than Placebo in primary analysis population



Exit survey: Percent reporting significant improvement in near vision

Key Safety Outcomes


Microline 2% vs Placebo

	MicroLine	Placebo
Mild, Transient Hyperemia	20%	7%
Instillation Discomfort	2%	0%
Brow ache*	3%	0%

*In eye drop formulations, brow ache with pilocarpine is known to occur in 20 – 25% of patients


VISION-2 Study Design

- Registrational, double-masked, placebo-controlled, cross-over superiority trial
 - Phase 3 (microdosed pilocarpine 2% versus placebo)
- Primary endpoint: binocular distance corrected near visual acuity
- Enrollment to commence 2H 2021



There Exists a Significant Unmet Need in Presbyopia

- Majority of presbyopia patients have never had to wear glasses prior to having difficulty with near vision
- Having to wear glasses can be an inconvenience and an outward signal of aging
- A “no glasses” option may be valuable and more convenient to patients
- Eyenovia’s MicroLine is intended to be a companion product to spectacles, not a replacement
 - Provides freedom to use the product *as needed*








18 million people 40-55 years of age who never previously needed glasses suffer from presbyopia in the US alone



A multi-billion-dollar
addressable market

- Effective at restoring functional vision, such as the ability to read a menu or cell phone
- Ability to use “as needed” without chronic dosing
- Rapid onset of action
- Easy to administer
- Low instance of side effects, particularly browache

Late-Stage Presbyopia Competitive Landscape

Company	API	Trial	Primary EP	Efficacy and Safety	Status
 eyenovia	Pilocarpine 2%	VISION-1 (40-60 YO)	Gain of 3 lines or more in mesopic, high contrast, binocular (DCNVA) at Hour 2 vs. placebo (vehicle)	Met primary EP Excellent tolerability	Completed; planning for VISION-2
 Allergan	Pilocarpine 1.25%	Gemini I, II (40-55 YO)	Gain of 3 lines or more in mesopic, high contrast, binocular (DCNVA) at Day 30, Hour 3 vs. placebo (vehicle)	Met primary EP Statements of 20% brow/headache	PDUFA H2 2021
 Ocuphire	Nyxol (phentolamine 0.75%) and pilocarpine	VEGA-1 (phase II)	Gain of 3 lines or more in photopic, binocular (DCNVA) over 6 hours vs. placebo (vehicle)	Not Yet Completed	Fully enrolled
 VISUS LABORATORIES	Brimochol (carbachol and brimonidine)	NCT04774237 (phase II)	Change from baseline in near VA	Not Yet Completed	Actively Recruiting; Topline expected mid 2021
 ORASIS PHARMACEUTICALS	Pilocarpine 0.2% and NSAID	NEAR-1 NEAR-2 (45-64 YO)	Gain of 3 lines or more at 40cm and no loss in BDCVA greater or equal to 5 letters at 4 meters on Day 8	Not Yet Completed	Actively Recruiting

MicroPine for Progressive Myopia



Progressive of Myopic Maculopathy

Affects ~25M children in the US alone, with ~5M considered to be at high risk⁴

- Back-of-the-eye disease
- Mostly begins in early childhood, with a genetic link to myopic parents¹
- Pathologic elongation of sclera/retina which can lead to significant morbidity and visual sequelae²
 - Retinal detachment
 - Myopic retinopathy
 - Vision loss
 - Quality of life
- Currently, no FDA-approved drug therapies to slow myopia progression
- Atropine may slow myopia progression by 60% or more³

Strategic Partnerships to Potentially Extend Commercial Reach



Arctic Vision

Validating partnership for the development and commercialization of **MicroPine** and **MicroLine**

Upfront payment: \$4M

Potential milestone payments and reimbursed development costs: \$41.75M

Commercial supply terms or royalties: mid-single digits

Territory: Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea

Impacted population estimated at approx. more than 8x the US¹



Bausch Health

Strategic partnership for the development and commercialization of **MicroPine**

Upfront payment: \$10M

Potential milestone payments and reimbursed development costs: \$50M *(Reimbursed development costs associated with Phase 3 CHAPERONE trial to begin immediately)*

Royalties on gross profit: mid-single digit to mid-teen percentages

Territory: US and Canada

US impacted population with high myopia estimated at approx. 3M^{2,3}

¹Min Chen, 2018

²Theophanous C. Myopia Prevalence and Risk Factors in Children. Clinical Ophthalmology. December 2018.


³U.S. Census Bureau, Current Population Survey, Annual Social and Economic Supplement, 2019.

Future Licensing Opportunities



MydCombi for Mydriasis

- Pharmacologic mydriasis (pupil dilation) is part of the comprehensive eye exam
 - Estimated 80 million office-based comprehensive and diabetic eye exams and 4 million ophthalmic surgical dilations performed annually in the United States
 - Essential for diabetic retinopathy, glaucoma and retina disease screening
 - An estimated \$250 million US market opportunity¹
- Places technology at the initial point-of-care with prescribers (ophthalmologists and optometrists)
- No direct contact increases patient safety by reducing potential cross contamination associated with the use of shared dilating drops in OD/OPH offices
- No anticipated reimbursement hurdles; expect to sell directly to ophthalmology and optometry practices
- NDA accepted March 2021






MydCombi

Tropicamide 1%/Phenylephrine 2.5%
Ophthalmic Spray

- If approved, the only fixed combination of the two leading mydriatic medications in the US
- Administered with the push of a button, saving up to ten minutes of technician time¹
- Touch-free, comfortable application with fewer than 1% of patients experiencing stinging discomfort²
- Lower drug and preservative exposure, including systemic absorption of phenylephrine, which can be problematic in hypertensive patients^{2,3}
- Reliable in numerous patient practices. More than 9 out of 10 patients achieved clinically significant mydriasis at 35 minutes post-dosage²

MydCombi has a Superior Mydriatic Effect vs. Single Agents

Pupil Diameter at Each Study Measurement Time by Treatment (Pooled PP Population)



Prompt Mydriasis

Mydriasis >5mm achieved in 88% of patients at 20 minutes, without the delay of instilling multiple drops

Superior Efficacy

MydCombi achieved superior efficacy over single-agent components

Office & Surgical Use

Mydriasis >6 mm achieved in >93% of patients at 35 minutes post-dosage which is clinically meaningful for both office retinal exam and surgical dilation

MydCombi Launch Expenses: A Fraction of a Typical Ophthalmic Drug Launch



Big Eye Pharma

<p>11 FTE for \$2.2 million</p> <p>Calling on large group practices in largest population centers for 50% reach at launch</p>	<p>Salesforce</p>	<p>100 FTE for \$20.0 million</p> <p>Calling on 18,000 doctors across the US for 80% reach at launch</p>
<p>Not needed.</p> <p>Product is a diagnostic bought by the practice.</p>	<p>Managed Care Group</p>	<p>8 FTE for \$1.6 million</p> <p>Often delay of up to 1 year to obtain formulary access.</p>
<p>\$2.0 million</p> <p>Glossy pieces and interactive programs are not needed. Key Account People will train and leave a sample for evaluation.</p>	<p>Promotion</p>	<p>\$10.0 million</p> <p>Dinner meetings, large convention booths, investigational grants, advertising, lunch and learns.</p>
<p>Total: ~\$4.2 million</p>		<p>Total: ~\$31.6 million</p>

Technology that has Multiple Layers of IP, Clinical and Regulatory Protection



Financial Snapshot

Nasdaq: EYEN

Common Shares Outstanding	25.6M
----------------------------------	-------

Equity Grants Outstanding Under Stock Plans	3.5M
--	------

Warrants	2.0M
-----------------	------

Fully Diluted Shares	31.1M
-----------------------------	-------

Cash	\$24.9M
-------------	---------

Debt (PPP loan)	\$0.5M
------------------------	--------

Board of Directors



Dr. Fred Eshelman
Chairman

Founder and former CEO of PPDI, founding chairman of Furiex Pharmaceuticals, and founder of Eshelman Ventures



Dr. Ernest Mario
Board Member

Former Chairman and CEO of Reliant Pharmaceuticals, ALZA, and Glaxo Holdings



Dr. Curt LaBelle
Board Member

Managing Director of GHIF venture fund and Co-Founder of Eyenovia



Kenneth Lee Jr.
Board Member

General partner of Hatteras Venture Partners



Charles Mather IV
Board Member

Managing Director, Equity Capital Markets at Suntrust Robinson Humphrey



Dr. Anthony Sun
Board Member

CEO, Zentaris Pharmaceuticals, Inc.



Dr. Sean Ianchulev
Board Member

CEO, CMO and Co-Founder of Eyenovia



Dr. Julia Haller
Board Member

Ophthalmologist-in-Chief
Wills Eye Hospital



eyenovia

Making it Possible

June 2021
